Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits

  • Laguna, Ariadna|||0000-0002-9732-6677
  • Peñuelas, Núria|||0000-0001-6443-9790
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Nicolau Vera, Alba|||0000-0002-0836-2802
  • Arthaud, Sébastien|||0000-0001-7271-5468
  • Guillard-Sirieix, Camille|||0000-0002-2645-1892
  • Lorente-Picón, Marina|||0000-0002-3629-9804
  • Compte, Joan|||0000-0001-5447-5122
  • Miquel-Rio, Lluís|||0000-0002-3547-6004
  • Xicoy, Helena|||0000-0001-6641-1222
  • Liu, Jiong
  • Parent, Annabelle|||0000-0002-6195-812X
  • Cuadros, Thais|||0000-0001-6994-2424
  • Romero-Giménez, Jordi|||0000-0002-8459-9895
  • Pujol, Gemma
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Fort, Patrice|||0000-0003-1211-8631
  • Bortolozzi, Analía|||0000-0002-2069-9192
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Vila Bover, Miquel|||0000-0002-1352-989X
One key limitation in developing effective treatments for neurodegenerative diseases is the lack of models accurately mimicking the complex physiopathology of the human disease. Humans accumulate with age the pigment neuromelanin inside neurons that synthesize catecholamines. Neurons reaching the highest neuromelanin levels preferentially degenerate in Parkinson's, Alzheimer's and apparently healthy aging individuals. However, this brain pigment is not taken into consideration in current animal models because common laboratory species, such as rodents, do not produce neuromelanin. Here we generate a tissue-specific transgenic mouse, termed tgNM, that mimics the human age-dependent brain-wide distribution of neuromelanin within catecholaminergic regions, based on the constitutive catecholamine-specific expression of human melanin-producing enzyme tyrosinase. We show that, in parallel to progressive human-like neuromelanin pigmentation, these animals display age-related neuronal dysfunction and degeneration affecting numerous brain circuits and body tissues, linked to motor and non-motor deficits, reminiscent of early neurodegenerative stages. This model could help explore new research avenues in brain aging and neurodegeneration. Unlike humans, rodents do not accumulate the brain pigment neuromelanin in catecholamine neurons with age. The transgenic mouse model here presented accumulates neuromelanin and mimics the early physiopathology of Parkinson's disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease

  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Compte, Joan|||0000-0001-5447-5122
  • Cuadros, Thais|||0000-0001-6994-2424
  • Nicolau Vera, Alba|||0000-0002-0836-2802
  • Guillard-Sirieix, Camille|||0000-0002-2645-1892
  • Peñuelas, Núria|||0000-0001-6443-9790
  • Lorente-Picon, Marina
  • Parent, Annabelle|||0000-0002-6195-812X
  • Romero-Giménez, Jordi|||0000-0002-8459-9895
  • Cladera-Sastre, Joana M.
  • Laguna, Ariadna|||0000-0002-9732-6677
  • Vila Bover, Miquel|||0000-0002-1352-989X
Humans accumulate with age the dark-brown pigment neuromelanin inside specific neuronal groups. Neurons with the highest neuromelanin levels are particularly susceptible to degeneration in Parkinson's disease, especially dopaminergic neurons of the substantia nigra, the loss of which leads to characteristic motor Parkinson's disease symptoms. In contrast to humans, neuromelanin does not appear spontaneously in most animals, including rodents, and Parkinson's disease is an exclusively human condition. Using humanized neuromelanin-producing rodents, we recently found that neuromelanin can trigger Parkinson's disease pathology when accumulated above a specific pathogenic threshold. Here, by taking advantage of this newly developed animal model, we assessed whether the intracellular build-up of neuromelanin that occurs with age can be slowed down in vivo to prevent or attenuate Parkinson's disease. Because neuromelanin derives from the oxidation of free cytosolic dopamine, we enhanced dopamine vesicular encapsulation in the substantia nigra of neuromelanin-producing rats by viral vector-mediated overexpression of vesicular monoamine transporter 2 (VMAT2). This strategy reduced the formation of potentially toxic oxidized dopamine species that can convert into neuromelanin and maintained intracellular neuromelanin levels below their pathogenic threshold. Decreased neuromelanin production was associated with an attenuation of Lewy body-like inclusion formation and a long-term preservation of dopamine homeostasis, nigrostriatal neuronal integrity and motor function in these animals. Our results demonstrate the feasibility and therapeutic potential of modulating age-dependent intracellular neuromelanin production in vivo, thereby opening an unexplored path for the treatment of Parkinson's disease and, in a broader sense, brain ageing. Neurons that accumulate the highest levels of neuromelanin with age are also the most susceptible to degeneration in Parkinson's disease. Using a neuromelanin-producing rat model, Gonzalez-Sepulveda, Compte et al. show that slowing down age-dependent neuromelanin production can help prevent Parkinson's disease-like features.